Literature DB >> 26156288

The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy.

Wooyoung Jang1,2, Hee Ju Kim3,4, Huan Li3, Kwang Deog Jo5, Moon Kyu Lee5, Hyun Ok Yang6.   

Abstract

Currently, the autophagy pathway is thought to be important for the pathogenesis of Parkinson's disease (PD), and the modulation of autophagy may be a novel strategy for the treatment of this disease. Erythropoietin (EPO) has been reported to have neuroprotective effects through anti-oxidative, anti-apoptotic, and anti-inflammatory mechanisms, and it has also been shown to modulate autophagy signaling in an oxygen toxicity model. Therefore, we investigated the effects of EPO on autophagy markers and evaluated its neuroprotective effect on rotenone-induced neurotoxicity. We adapted the rotenone-induced neurotoxicity model to SH-SY5Y cells as an in vitro model of PD. We measured cell viability using MTT and annexin V/propidium iodide assays and measured intracellular levels of reactive oxygen species. Immunofluorescence analysis was performed to measure the expression of LC3 and α-synuclein. Intracellular signaling proteins associated with autophagy were examined by immunoblot analysis. EPO mono-treatment increased the levels of mammalian target of rapamycin (mTOR)-independent/upstream autophagy markers, including Beclin-1, AMPK, and ULK-1. Rotenone treatment of SH-SY5Y cells reduced their viability, increased reactive oxygen species levels, and induced apoptosis and α-synuclein expression, and simultaneous exposure to EPO significantly reduced these effects. Rotenone enhanced mTOR expression and suppressed Beclin-1 expression, indicating suppression of the autophagy system. However, combined treatment with EPO restored Beclin-1 expression and decreased mTOR expression. EPO protects against rotenone-induced neurotoxicity in SH-SY5Y cells by enhancing autophagy-related signaling pathways. The experimental evidence for the EPO-induced neuroprotection against rotenone-induced dopaminergic neurotoxicity may significantly impact the development of future PD treatment strategies.

Entities:  

Keywords:  Autophagy; Erythropoietin; Neuroprotection; Parkinson’s disease

Mesh:

Substances:

Year:  2015        PMID: 26156288     DOI: 10.1007/s12035-015-9316-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  48 in total

Review 1.  Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models.

Authors:  Sandra Juul
Journal:  Clin Perinatol       Date:  2004-03       Impact factor: 3.430

2.  Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis.

Authors:  Yushan Zhu; Lixia Zhao; Lei Liu; Ping Gao; Weili Tian; Xiaohui Wang; Haijing Jin; Haidong Xu; Quan Chen
Journal:  Protein Cell       Date:  2010-06-04       Impact factor: 14.870

3.  Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease.

Authors:  Nicholas M Kanaan; Timothy J Collier; Deanna M Marchionini; Susan O McGuire; Matthew F Fleming; Caryl E Sortwell
Journal:  Brain Res       Date:  2005-12-20       Impact factor: 3.252

4.  Use of Cuban recombinant human erythropoietin in Parkinson's disease treatment.

Authors:  Ivonne Pedroso; María Luisa Bringas; Anubis Aguiar; Lilia Morales; Mario Alvarez; Pedro A Valdés; Lázaro Alvarez
Journal:  MEDICC Rev       Date:  2012-01       Impact factor: 0.583

Review 5.  Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy.

Authors:  Chen-Chen Tan; Jin-Tai Yu; Meng-Shan Tan; Teng Jiang; Xi-Chen Zhu; Lan Tan
Journal:  Neurobiol Aging       Date:  2013-11-28       Impact factor: 4.673

Review 6.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.

Authors:  Anthony H V Schapira; C Warren Olanow
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

7.  alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.

Authors:  Maria Xilouri; Tereza Vogiatzi; Kostas Vekrellis; Leonidas Stefanis
Journal:  Autophagy       Date:  2008-10-26       Impact factor: 16.016

8.  LAMP2A as a therapeutic target in Parkinson disease.

Authors:  Maria Xilouri; Oeystein Roed Brekk; Deniz Kirik; Leonidas Stefanis
Journal:  Autophagy       Date:  2013-10-08       Impact factor: 16.016

9.  Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.

Authors:  Maria Xilouri; Tereza Vogiatzi; Kostas Vekrellis; David Park; Leonidas Stefanis
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

10.  Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models.

Authors:  Sami J Barmada; Andrea Serio; Arpana Arjun; Bilada Bilican; Aaron Daub; D Michael Ando; Andrey Tsvetkov; Michael Pleiss; Xingli Li; Daniel Peisach; Christopher Shaw; Siddharthan Chandran; Steven Finkbeiner
Journal:  Nat Chem Biol       Date:  2014-06-29       Impact factor: 15.040

View more
  34 in total

1.  Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship.

Authors:  Mingjun Shi; Brianna Flores; Peng Li; Nancy Gillings; Kathryn L McMillan; Jianfeng Ye; Lily Jun-Shen Huang; Sachdev S Sidhu; Yong-Ping Zhong; Maria T Grompe; Philip R Streeter; Orson W Moe; Ming Chang Hu
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

2.  Charting a course for erythropoietin in traumatic brain injury.

Authors:  Kenneth Maiese
Journal:  J Transl Sci       Date:  2016-03-26

Review 3.  Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2016       Impact factor: 1.990

Review 4.  The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Biochem Soc Trans       Date:  2018-03-09       Impact factor: 5.407

5.  Recombinant Human Erythropoietin Protects Against Hippocampal Damage in Developing Rats with Seizures by Modulating Autophagy via the S6 Protein in a Time-Dependent Manner.

Authors:  Qinrui Li; Ying Han; Junbao Du; Hongfang Jin; Jing Zhang; Manman Niu; Jiong Qin
Journal:  Neurochem Res       Date:  2017-12-13       Impact factor: 3.996

Review 6.  Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2017       Impact factor: 1.990

Review 7.  Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2018       Impact factor: 1.990

8.  Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative disease.

Authors:  Kenneth Maiese
Journal:  Int Rev Neurobiol       Date:  2020-08-11       Impact factor: 3.230

Review 9.  Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways.

Authors:  Kenneth Maiese
Journal:  Expert Rev Clin Pharmacol       Date:  2020-01-03       Impact factor: 5.045

10.  Regeneration in the nervous system with erythropoietin.

Authors:  Kenneth Maiese
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.